Journal of Internal Medicine Concepts & Practice››2021,Vol. 16››Issue (04): 272-275.doi:10.16138/j.1673-6087.2021.04.011
• Review artice •Previous ArticlesNext Articles
Received:2021-03-10Online:2021-07-30Published:2022-07-25| [1] | Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis[J]. Mol Cell, 2001, 8(3): 705-711. pmid:11583631 |
| [2] | Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences[J]. Mol Cell, 2016, 61(5): 695-704. doi:10.1016/j.molcel.2016.02.019URL |
| [3] | Certo M, Del Gaizo Moore V, Nishimo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members[J]. Cancer Cell, 2006, 9(5): 351-365. doi:10.1016/j.ccr.2006.03.027URL |
| [4] | Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia[J]. Cancer Cell, 2004, 6(3): 241-249. doi:10.1016/j.ccr.2004.07.011URL |
| [5] | Reed JC. A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation?[J]. Leuk Res, 1996, 20(2): 109-111. doi:10.1016/0145-2126(95)00135-2URL |
| [6] | Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia[J]. Blood, 2003, 101(2): 425-432. doi:10.1182/blood-2002-06-1899pmid:12393493 |
| [7] | Fesik SW. Insights into programmed cell death through structural biology[J]. Cell, 2000, 103(2): 273-282. pmid:11057900 |
| [8] | Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors[J]. Cell Death Differ, 2009, 16(7): 1030-1039. doi:10.1038/cdd.2009.48pmid:19390557 |
| [9] | Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681. doi:10.1038/nature03579URL |
| [10] | Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase Ⅰ study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30(5): 488-496. doi:10.1200/JCO.2011.34.7898pmid:22184378 |
| [11] | Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discov, 2014, 4(3): 362-375. doi:10.1158/2159-8290.CD-13-0609URL |
| [12] | Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase Ⅱ Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia[J]. Cancer Discov, 2016, 6(10): 1106-1117. pmid:27520294 |
| [13] | Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells[J]. Ann Hematol, 2012, 91(12): 1861-1870. doi:10.1007/s00277-012-1537-8URL |
| [14] | Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1[J]. Leukemia, 2018, 32(2): 303-312. doi:10.1038/leu.2017.243pmid:28751770 |
| [15] | Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia[J]. Nat Med, 2018, 24(12): 1859-1866. doi:10.1038/s41591-018-0233-1pmid:30420752 |
| [16] | DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(2): 216-228. doi:10.1016/S1470-2045(18)30010-XURL |
| [17] | Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidinevsconventional care regimens in older patients with newly diagnosed AML with >30% blasts[J]. Blood, 2015, 126(3): 291-299. doi:10.1182/blood-2015-01-621664pmid:25987659 |
| [18] | Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-Dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ⅰb/Ⅱ study[J]. J Clin Oncol, 2019, 37(15): 1277-1284. doi:10.1200/JCO.18.01600URL |
| [19] | DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. Engl J Med, 2020, 383(7): 617-629. doi:10.1056/NEJMoa2012971URL |
| [20] | Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial[J]. Blood, 2020, 135(24): 2137-2145. doi:10.1182/blood.2020004856URL |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
